The UNAIDS director also warned that US funding cuts could be dire for global efforts to curb HIV. View on euronews ...

The head of the U.N. AIDS agency says the sudden loss of American money has been “devastating” for efforts to stop HIV and ...

A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...